Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 36: 1918-1921, 1990;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuwana, T.
Right arrow Articles by Rosalki, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuwana, T.
Right arrow Articles by Rosalki, S. B.

Clinical Chemistry, Vol 36, 1918-1921, Copyright © 1990 by American Association for Clinical Chemistry

Intestinal variant alkaline phosphatase in plasma in disease [published erratum appears in Clin Chem 1991 Jun;37(6):886]

T Kuwana and SB Rosalki
Department of Chemical Pathology and Human Metabolism, Royal Free Hospital, London, U.K.

We investigated by enzyme electrophoresis after prolonged neuraminidase treatment the activity of "intestinal variant" (alpha 2-globulin mobility) alkaline phosphatase (EC 3.1.3.1; ALP) in the plasma of 189 patients selected for disorders (diabetes mellitus, liver cirrhosis, and chronic renal failure) with a known high frequency of increased plasma intestinal (beta-globulin mobility) ALP activity. The overall frequency of the variant ALP was 23.8%, whereas in the samples showing intestinal ALP it was 45.0%. The variant ALP was not observed in the absence of intestinal ALP, nor in patients of blood group A. Its frequency did not differ significantly between the different patient groups. Quantification of the variant ALP by densitometry was unsatisfactory but the quantity could be estimated by subtracting the intestinal ALP activity measured by electrophoresis from the activity determined by immunoassay with monoclonal antibody that reacts with both the intestinal and the variant forms. This indicated median activity of 12 U/L for the variant, approximately equal to that of the concomitant intestinal ALP. From the effects of papain and bromelain treatments, we suggest that "intestinal variant" represents intestinal ALP with attached membrane-binding domain.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
H. Zetterberg
Increased Serum Concentrations of Intestinal Alkaline Phosphatase in Peritoneal Dialysis
Clin. Chem., March 1, 2005; 51(3): 675 - 676.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Ognibene, L. Pala, G. Messeri, C. M. Rotella, and P. Berti
Relations between Intestinal Alkaline Phosphatase Activity and Insulin Secretion in Obese Patients
Clin. Chem., September 1, 1997; 43(9): 1672 - 1673.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Association for Clinical Chemistry.